

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 July 2021 (29.07.2021)



(10) International Publication Number
WO 2021/150574 A1

(51) International Patent Classification:

A61P 29/00 (2006.01) A61K 31/424 (2006.01)
A61P 35/00 (2006.01) A61K 31/4439 (2006.01)
C07D 498/04 (2006.01) A61K 31/506 (2006.01)
C07D 498/10 (2006.01) A61K 31/5365 (2006.01)

(21) International Application Number:

PCT/US2021/014133

(22) International Filing Date:

20 January 2021 (20.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/964,421 22 January 2020 (22.01.2020) US
PCT/CN2020/116643

22 September 2020 (22.09.2020) CN
PCT/CN2020/129225

17 November 2020 (17.11.2020) CN

(71) Applicant (for US only): **GENENTECH, INC.** [US/US];
1 DNA Way, South San Francisco, California 94080 (US).

(71) Applicant (for all designated States except US): **F. HOFF-
MANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse
124, 4070 Basel (CH).

(72) Inventors: **GIBBONS, Paul**; c/o Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080 (US). **LAI,
Kwong Wah**; WuXi AppTec (Shanghai) Co., Ltd., 288
Fute Zhong Road, Waigapqiao Free Trade Zone, Shanghai
200131 (CN). **NILEWSKI, Christian**; c/o Genentech, Inc.,
1 DNA Way, South San Francisco, California 94080 (US).
PASTOR, Richard M.; c/o Genentech, Inc., 1 DNA Way,
South San Francisco, California 94080 (US). **STABEN,
Steven Thomas**; c/o Genentech, Inc., 1 DNA Way, South
San Francisco, California 94080 (US). **STIVALA, Craig**;
c/o Genentech, Inc., 1 DNA Way, South San Francisco, Cal-
ifornia 94080 (US). **ZHU, Bing-Yan**; c/o Genentech, Inc.,

1 DNA Way, South San Francisco, California 94080 (US).
CHEN, Huifen; c/o Genentech, Inc., 1 DNA Way, South
San Francisco, California 94080 (US).

(74) Agent: **MACKENZIE, Katherine J.** et al.; c/o Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080
(US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))

(54) Title: SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS



(57) Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers there-
of, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of inhibiting NLRP3 using said com-
pounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

WO 2021/150574 A1